[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"National University Health System, Singapore\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":250},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,41,64,91,114,133,161,187,216],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":4},"100647879","midlife-empowerment-and-longevity-through-optimizing-wellness-100647879",false,"NCT07713862","Midlife Empowerment and Longevity Through Optimizing Wellness","Enhancing Healthy Longevity in At-Risk Midlife Women With Abdominal Obesity: A Digital Phenotyping Commitment Device on Improving Visceral Body Fat Mass, Menopausal Symptoms and Cardiometabolic Risk Factors","MELOW","Inclusion Criteria:\n\n* Women aged 21-65 years old;\n* Report at least mild climacteric symptoms as indicated by an MRS score ≥5;\n* Waist circumference ≥80 cm, indicating abdominal adiposity;\n* Own and use a smartphone compatible with the CGM and Oura Ring.\n\nExclusion Criteria:\n\n* Are currently receiving hormone replacement therapy (HRT);\n* Are currently using oral contraceptives;\n* Have been diagnosed with severe psychiatric illness requiring inpatient care;\n* Are concurrently enrolled in another behavioural or psychotherapy trial;\n* Have significant cognitive impairment or inability to engage with digital tools;\n* Have uncontrolled chronic medical conditions that may interfere with study participation;\n* Unable to comprehend written and spoken English.","FEMALE","21 Years","65 Years",{"count":21,"type":22},200,"ESTIMATED","INTERVENTIONAL",[25],"NA","The goal of this observational longitudinal study is to understand how lifestyle behaviours, menopausal symptoms, and digital health data change over time in women experiencing perimenopause or menopause, and to evaluate whether a personalised digital health programme can support healthier lifestyle behaviours and improve cardiometabolic health.\n\nThe main questions it aims to answer are:\n\n1. Can personalised lifestyle recommendations informed by wearable devices, dietary logging, and self-reported symptoms improve adherence to healthy diet, physical activity, and sleep behaviours?\n2. How are menopausal symptoms associated with changes in cardiometabolic health, body composition, physical function, and quality of life over time?\n\nParticipants will:\n\n1. Attend study visits at the National University of Singapore for health assessments, including measurements of body composition, physical function, and cardiometabolic health.\n2. Wear a smartwatch or wearable device to monitor physiological and activity data throughout the study.\n3. Use a mobile application to record dietary intake, menopausal symptoms, and other health-related information.\n4. Receive personalised lifestyle recommendations based on their health data and engage in regular follow-up assessments over the study period.",[28],"Menopause","NOT_YET_RECRUITING","2026-07-22",{"date":32,"type":33},"2026-07-23","ACTUAL",{"date":35,"type":22},"2027-01",{"date":37,"type":22},"2030-01",{"name":39,"class":40},"National University Health System, Singapore","OTHER",{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":48,"minAge":18,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":23,"phases":51,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":63},"100647641","effectiveness-of-the-personalized-responses--integrated-systems-for-metabolism-prism-on-improving-insulin-resistance-among-adults-with-metabolic-syndrome-a-pilot-study-prism-i-100647641","NCT07710274","Effectiveness of the Personalized Responses & Integrated Systems for Metabolism (PRISM) on Improving Insulin Resistance Among Adults With Metabolic Syndrome: A Pilot Study (PRISM-I)","PRISM-I","Inclusion Criteria:\n\nParticipants will be included for if they are:\n\n* (1) adults aged 21-70 years old;\n* (2) willing and able to comply with using a CGM, smart ring, food logging app\n* (3) able to provide written informed consent;\n* (4) English-speaking and literate;\n* (5) meet the inclusion criteria for metabolic syndrome and insulin resistance.\n* The criteria for insulin resistance is HOMA-IR ≥ 2.5.\n* The criteria for metabolic syndrome is to have high waist circumference (≥ 80cm for females and ≥ 90cm for males); and any two of the four below:\n* (1) raised triglycerides: 1.7 mmol\u002FL or on treatment;\n* (2) reduced HDL cholesterol: \\\u003C 1.0 mmol\u002FL (40 mg\u002FdL) in men, \\\u003C 1.3 mmol\u002FL (50 mg\u002FdL) in women, or on treatment;\n* (3) high blood pressure: 130\u002F85 mmHg or on treatment; or\n* (4) raised fasting glucose: 5.6 mmol\u002FL (100 mg\u002FdL) or previously diagnosed with T2DM\n\nExclusion Criteria:\n\nParticipants will be excluded from both phases if they are:\n\n* (1) on insulin therapy;\n* (2) are pregnant or lactating;\n* (3) have a medical condition or are on a treatment that may interfere with study participation or metabolic assessments, as determined by the study investigators;\n* (4) currently participating in other lifestyle modification programs.","ALL","70 Years",{"count":21,"type":22},[25],"The primary objective of the Personalized Responses \\& Integrated Systems for Metabolism (PRISM-I) pilot study is to assess the feasibility of conducting a definitive randomized controlled trial evaluating precision lifestyle interventions for improving insulin resistance in adults with metabolic syndrome.",[54],"Metabolic Syndrome (MetS)","2026-07-15",{"date":57,"type":33},"2026-07-17",{"date":59,"type":22},"2026-07",{"date":61,"type":22},"2027-07",{"name":39,"class":40},1,{"id":65,"slug":66,"hasResults":11,"nctId":67,"briefTitle":68,"officialTitle":68,"acronym":69,"eligibilityCriteria":70,"healthyVolunteers":11,"sex":48,"minAge":18,"maxAge":4,"enrollmentInfo":71,"targetDuration":4,"studyType":23,"phases":73,"briefSummary":75,"conditions":76,"keywords":79,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":63},"100646200","phase-2-bepirovirsen-liver-biopsy-study-100646200","NCT07696520","Bepirovirsen Liver Biopsy Study","GSK Biopsy","Inclusion Criteria:\n\n1. At least 21 years of age at the time of signing the informed consent.\n2. Documented to be HBsAg positive for ≥ 6 months prior to Screening.\n3. Currently receiving stable NA therapy (defined as no changes to their NA regimen from at least 6 months prior to Screening and with no planned changes to the stable regimen over the duration of the study), or not receiving any Hepatitis B treatment for at least 6 months, or Hepatitis B treatment naïve.\n4. qHBsAg ≤1000 IU\u002Fml\n5. Alanine aminotransferase (ALT) ≤2x ULN\n6. A female participant is eligible to participate if she is not pregnant or breastfeeding, and 1 of the following conditions applies:\n\n   * Is a woman of non-childbearing potential\n   * Is a woman of childbearing potential and using a contraceptive method\n7. Capable of giving signed informed consent\n\nExclusion Criteria:\n\n1. qHBsAg \\> 1000 IU\u002Fml\n2. Do not consent to participate in the Bepirovirsen Liver Biopsy study\n3. Clinically significant abnormalities or clinically significant physical examination findings (e.g. major surgery within 3 months of screening)\n4. Past history of or current co-infection with Hepatitis C infection, Human immunodeficiency virus (HIV) or Hepatitis D virus\n5. History of or liver cirrhosis as determined by:\n\n   1. Fibroscan \\> 12kPa\n   2. Participant's historic record of either\u002Fboth liver biopsy or liver stiffness measurements in their medical records where their results are Liver biopsy Metavir Score is F4, they will be excluded from the study(If the participant has inconsistent clinical picture of cirrhosis, confirm and discuss eligibility with an investigator)\n6. Diagnosed with hepatocellular carcinoma as evidenced by Alpha-fetoprotein concentration ≥200 ng\u002FmL or if the screening alpha fetoprotein concentration is ≥50 ng\u002FmL and \\\u003C200 ng\u002FmL, the absence of liver mass must be documented by imaging within 6 months of or at screening. Cases should be discussed with an investigator.\n7. History of malignancy within the past 5 years with the exception of specific cancers that are cured by surgical resection (e.g., skin cancer). Participants under evaluation for possible malignancy are not eligible.\n8. History of vasculitis or presence of symptoms and signs of potential vasculitis, current or history of an autoimmune condition or history\u002Fpresence of other diseases that may be associated with vasculitis condition\n9. History of extrahepatic disorders possibly related to HBV immune conditions\n10. Current\u002FHistory of alcohol or drug abuse\u002Fdependence as judged by the investigator to potentially interfere with participant compliance\n11. Currently taking, or took within 3 months of screening, any immunosuppressing drugs, other than a short course of therapy (≤2 weeks) or topical\u002Finhaled steroid use.\n12. Participants requiring anti-coagulation therapies or anti-platelet agents unless treatment can safely be discontinued throughout duration of Bepirovirsen treatment, by the discretion of the investigator. Occasional use is permitted.\n13. The participant has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 5 half-lives (if known) or twice the duration (if known) of the biological effect of the study treatment (whichever is longer) or 90 days (if half-life or duration is unknown).\n14. Prior treatment with any oligonucleotide or siRNA within 12 months prior to the first dosing day\n15. Prior treatment with Bepirovirsen within 6 months\n16. Fridericia's QT correction formula (QTcF) ≥450 msec (if single ECG at screening shows QTcF ≤450 msec, a mean of triplicate measurements should be used to confirm that participant meets exclusion criterion).\n17. Laboratory results as follows:\n\n    1. Serum albumin ≤3.5 g\u002FdL\n    2. Glomerular filtration rate (GFR) ≤60 mL\u002Fmin\u002F1.73m2 as calculated by the CKD-EPI formula\n    3. INR \\>1.25\n    4. Platelet count \\\u003C140 x 109\u002FL\n    5. Total bilirubin \\>1.25x ULN (For participants with benign unconjugated hyperbilirubinemia with total bilirubin \\>1.25x ULN, discussion for inclusion to the study is required with the investigator)\n    6. Urine albumin to creatinine ratio (uACR) \\>0.3 mg\u002Fmg (or \\>300 mg\u002Fg). (In the event of an uACR above this threshold, eligibility may be confirmed by a second measurement. In cases where results are shown as unable to perform (UTP), please check the individual labs and confirm that the participant has urine albumin and\u002For urine creatinine within normal levels. The investigator should confirm that the participant does not have a history of medical conditions or other risk factors that may affect renal function)\n18. History of\u002Fsensitivity to Bepirovirsen or components thereof or a history of drug or other allergy that, in the opinion of the investigator, contraindicates their participation.",{"count":72,"type":22},30,[74],"PHASE2","Bepirovirsen Liver Biopsy study is a single centre open label phase II study to examine the antiviral and immunological effects of bepirovirsen in CHB patients both treated and untreated with HBsAg\\\u003C1000 IU\u002Fml",[77,78],"HEPATITIS B CHRONIC","Hepatitis B Chronic Infection",[80,81,82],"hepatitis B","Bepirovirsen","Liver Biopsy","2026-07-06",{"date":85,"type":33},"2026-07-10",{"date":87,"type":22},"2026-07-01",{"date":89,"type":22},"2028-04-30",{"name":39,"class":40},{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":96,"acronym":4,"eligibilityCriteria":97,"healthyVolunteers":11,"sex":48,"minAge":18,"maxAge":19,"enrollmentInfo":98,"targetDuration":4,"studyType":23,"phases":100,"briefSummary":101,"conditions":102,"keywords":4,"overallStatus":105,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":63},"100624859","improving-ldl-c-levels-through-temporal-self-regulation-theory-based-personality-tailored-health-messages-100624859","NCT07415109","Improving LDL-C Levels Through Temporal Self-regulation Theory-based, Personality-tailored Health Messages","Improving LDL-C Levels Through Temporal Self-regulation Theory-based, Personality-tailored Health Messages: A Three-Arm Randomized Controlled Trial","Inclusion Criteria:\n\n* New participants of RESET who have given consent to be contacted for future studies\n* ≥21 years old\n\nExclusion Criteria:\n\n* are not able to read, write or communicate in English",{"count":99,"type":22},3000,[25],"The study is meant to run parallel to the larger study, RESET. The goal of this study is to to evaluate the effectiveness of a once-off general and personality-tailored text message on GP consultation among RESET participants identified to have high LDL-C. The main question it aims to answer is:\n\nWill participants exposed to personality tailored advice have a higher adherence to GP consultation compared to the participants in the control group?\n\nResearchers will compare a personalized message to a general message (with no personalization according to patients personality type) and control group to see if the messages increase adherence.\n\nParticipants are required to complete two questionnaires: one before and one after they receive their RESET results.",[103,104],"Adherence","Preventive Health Services","RECRUITING","2026-04-07",{"date":108,"type":33},"2026-04-13",{"date":110,"type":33},"2025-11-25",{"date":112,"type":22},"2028-11",{"name":39,"class":40},{"id":115,"slug":116,"hasResults":11,"nctId":117,"briefTitle":118,"officialTitle":118,"acronym":119,"eligibilityCriteria":120,"healthyVolunteers":11,"sex":48,"minAge":18,"maxAge":19,"enrollmentInfo":121,"targetDuration":4,"studyType":23,"phases":123,"briefSummary":124,"conditions":125,"keywords":4,"overallStatus":105,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":132,"locationsCount":63},"100624491","effectiveness-and-implementation-of-a-community-based-health-coach-led-artificial-intelligence-ai-powered-digital-self-regulation-program-for-individuals-with-metabolic-syndrome-mets-100624491","NCT07410325","Effectiveness and Implementation of a Community-based Health Coach-led Artificial Intelligence (AI)-Powered Digital Self-Regulation Program for Individuals With Metabolic Syndrome (MetS)","LIGHTER-MetS","Inclusion Criteria:\n\n1. are between 21 to 65 years of age;\n2. have a waist circumference ≥90 cm in men and ≥80 cm in women;\n3. have 2 or more of the following to be classified as having metabolic syndrome:\n\n   * triglyceride level of ≥1.7 mmol\u002FL or on specific treatment for this lipid abnormality;\n   * high density lipoprotein (HDL) cholesterol \\\u003C1.03 mmol\u002FL in men, and \\\u003C1.29 mmol\u002FL in women, or on specific treatment for this lipid abnormality;\n   * blood pressure of ≥130\u002F85 mmHg or on treatment of previously diagnosed hypertension;\n   * fasting blood glucose level of ≥ 5.6 mmol\u002FL or previously diagnosed type 2 diabetes;\n4. are not receiving other structured lifestyle modification programs;\n5. consent to audio-recording;\n6. English speaking and literate.\n\nExclusion Criteria:\n\n1. underwent or are scheduled for metabolic surgery within 1 year;\n2. are pregnant or planning for pregnancy at the time of recruitment;\n3. are unable to speak English;\n4. do not own a smartphone; and\n5. are unable to provide informed consent.",{"count":122,"type":22},316,[25],"This study aims to evaluate the effectiveness of the Lifestyle Intervention for Gentle, Healthy Transformation and Enhanced Weight Reduction-metabolic syndrome (LIGHTER-MetS) program on dietary self-regulation and cardiovascular risk among individuals with metabolic syndrome (MetS). The LIGHTER-MetS program, a community-based, grassroots-led initiative, integrates health coaching with the eTRIP© app to promote sustainable lifestyle changes focusing on diet, exercise, and emotion regulation.",[54,126],"Metabolic Syndrome",{"date":128,"type":33},"2026-04-08",{"date":130,"type":33},"2026-01-01",{"date":35,"type":22},{"name":39,"class":40},{"id":134,"slug":135,"hasResults":11,"nctId":136,"briefTitle":137,"officialTitle":138,"acronym":4,"eligibilityCriteria":139,"healthyVolunteers":11,"sex":48,"minAge":140,"maxAge":141,"enrollmentInfo":142,"targetDuration":4,"studyType":23,"phases":144,"briefSummary":145,"conditions":146,"keywords":148,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":154,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":160,"locationsCount":63},"100605885","effectiveness-of-two-icodextrin-exchanges-on-fluid-status-and-blood-pressure-control-compared-to-a-single-icodextrin-exchange-100605885","NCT07168343","Effectiveness of Two Icodextrin Exchanges on Fluid Status and Blood Pressure Control Compared to a Single Icodextrin Exchange","The Effect of Two Icodextrin Exchanges on Fluid Status and Blood Pressure Control in Children on Chronic Peritoneal Dialysis","Inclusion Criteria:\n\n1. Children 5-18 years of age\n2. Receiving CAPD or CCPD for at least the preceding 4 weeks, and not likely to change from CAPD to CCPD during the study period\n3. 24-hour mean arterial pressure (MAP; measured by ambulatory blood pressure monitoring (ABPM) above the 95th percentile for age, sex, and height\n4. 24-hour urine output less than 200ml\u002Fday\n\nExclusion Criteria:\n\n1. Children under 5 years of age (as younger children are more prone to hyponatremia)\n2. Children with systolic BP \\\u003C 50th centile for age, sex, and height in the preceding 4 weeks)\n3. Children who are polyuric or those prone to hypotension (defined as \\> 2 episodes of systolic BP \\\u003C 5th centile in the 4 weeks preceding the study)\n4. Known allergy to starch\n5. Pregnant women\n6. Patients with maltose or isomaltose intolerance, glycogen storage disease, pre-existing severe lactic acidosis, uncorrectable mechanical defects that prevent effective PD or increase the risk of infection and documented loss of peritoneal function or extensive adhesions that compromise peritoneal function","5 Years","18 Years",{"count":143,"type":22},10,[25],"Fluid overload and hypertension are prevalent in children undergoing chronic peritoneal dialysis (PD), especially in low- and middle-income countries (LMICs). These complications often lead to increased hospitalizations, higher medication use, and, in some cases, conversion to hemodialysis. Icodextrin is used to enhance ultrafiltration (UF) and reduce glucose exposure, but its effectiveness in children with a single long dwell has been inconsistent. Preliminary observations suggest that shorter, twice-daily icodextrin exchanges may improve UF and blood pressure (BP) control. However, no randomized trial has evaluated this approach in pediatric patients.",[147],"Children on Chronic Peritoneal Dialysis",[149,150,151,152],"Children","CAPD","CCPD","Icodextrin","2026-01-18",{"date":155,"type":33},"2026-01-21",{"date":157,"type":22},"2026-02-28",{"date":159,"type":22},"2028-06-30",{"name":39,"class":40},{"id":162,"slug":163,"hasResults":11,"nctId":164,"briefTitle":165,"officialTitle":166,"acronym":4,"eligibilityCriteria":167,"healthyVolunteers":11,"sex":48,"minAge":168,"maxAge":141,"enrollmentInfo":169,"targetDuration":4,"studyType":23,"phases":171,"briefSummary":172,"conditions":173,"keywords":174,"overallStatus":105,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":186,"locationsCount":63},"100603290","comparing-conventional-continuous-ambulatory-peritoneal-dialysis-prescription-c-capd-with-modified-capd-m-capd-prescription-in-children-with-end-stage-kidney-disease-from-low-resource-settings-100603290","NCT07134595","Comparing Conventional Continuous Ambulatory Peritoneal Dialysis Prescription (C-CAPD) With Modified-CAPD (M-CAPD) Prescription in Children With End-stage Kidney Disease From Low-resource Settings","A Multicenter Study Comparing Conventional Continuous Ambulatory Peritoneal Dialysis Prescription (C-CAPD) With Modified-CAPD (M-CAPD) Prescription in Delivering High Quality Goal-directed Peritoneal Dialysis in Children With End-stage Kidney Disease From Low-resource Settings: MaxED-OUT Trial","Inclusion Criteria:\n\n* CKD 5D who have been on peritoneal dialysis for at least three months.\n\nExclusion Criteria:\n\n1. Patients with BSA of ≥1.5 m2,\n2. Evidence of mechanical causes of low ultrafiltration capacity (hernia, peri-catheter, or genital leaks, pleuroperitoneal communication),\n3. Peritoneal membrane failure (encapsulating peritoneal sclerosis),\n4. Recent episode of peritonitis (within two months)\n5. Those who have been on hemodialysis before switching to PD in the last three weeks.","2 Years",{"count":170,"type":22},44,[25],"This study aims to compare modified CAPD (M-CAPD) and conventional CAPD (C-CAPD) in terms of delivering high-quality, goal-directed PD as well as avoiding resource wastage in prevalent ESKD patients aged 2 to ≤18 years using a randomized cross-over study design for one year.\n\nThis study hypothesizes that M-CAPD will have better ultrafiltration and solute clearance than C-CAPD.\n\nSpecific objectives\n\n1. To determine the ultrafiltration efficiency by measuring the following:\n\n   1. Clinical parameters: blood pressure, weight, evidence of fluid overload by the presence of edema, abnormal heart sounds (S3 gallop), lung crackles or rales, increased heart rate (tachycardia), rapid breathing (tachypnea),\n   2. Change in the number of blood pressure medications before and after the intervention,\n   3. Absolute and relative fluid overload using bioimpedance analyzer (BIA),\n   4. Mean daily ultrafiltration (UF) or Total 24-h UF,\n   5. Residual kidney function: 24-hour urine output,\n   6. Glucose exposure\n2. To determine the solute clearance adequacy by measuring the following:\n\n   1. Serum sodium, chloride, potassium, bicarbonate, serum albumin, calcium, and hemoglobin,\n   2. Phosphate clearance\n   3. Renal and peritoneal Kt\u002FVurea\n   4. Normalized protein catabolic rate (nPCR)\n3. To measure caregiver burden using a Paediatric Renal Caregiver Burden Scale (PR-CBS).",[147],[175,176,177,149,178],"M-CAPD","C-CAPD","ESKD","Low-resource settings","2025-08-19",{"date":181,"type":33},"2025-08-21",{"date":183,"type":33},"2024-11-18",{"date":185,"type":22},"2026-06-30",{"name":39,"class":40},{"id":188,"slug":189,"hasResults":11,"nctId":190,"briefTitle":191,"officialTitle":192,"acronym":193,"eligibilityCriteria":194,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":195,"enrollmentInfo":196,"targetDuration":4,"studyType":198,"phases":4,"briefSummary":199,"conditions":200,"keywords":207,"overallStatus":105,"whyStopped":4,"lastUpdateSubmitDate":209,"lastUpdatePostDateStruct":210,"startDateStruct":212,"completionDateStruct":214,"leadSponsor":215,"locationsCount":63},"100557792","studying-phenotypes-of-gestational-diabetes-mellitus-in-an-asian-pregnant-cohort-100557792","NCT06542718","Studying Phenotypes of Gestational Diabetes Mellitus in an Asian Pregnant Cohort","Studying the Heterogeneity of Gestational Diabetes Mellitus: Cardio-Metabolic Alteration and Treatment Response in a Multi-Ethnic Population in Singapore (GDM-CARE)","GDM-CARE","Inclusion Criteria:\n\n* Gestational age of ≤ 13 weeks 6 days\n* Overweight and obese subjects with BMI of 23kg\u002Fm² - 24.9kg\u002Fm² and ≥ 25.0kg\u002Fm², respectively\n* Aged 21-45 years with singleton pregnancy\n* Plan to be followed up during the whole pregnancy and deliver at NUH\n* Chinese, Malay or Indian ethnicity for pregnant subject\n* Can complete questionnaires in English language\n* Willing to wear continuous glucose monitoring device at least for 7 days at each required clinic visit\n\nExclusion Criteria:\n\n* Participants who are not Singapore citizens or Singapore Permanent Residents, not intending to eventually deliver in Singapore National University Hospital and to reside in Singapore for the next 2 years\n* Have serious skin conditions (eg. eczema) that precludes wearing the sensor for 14 days\n* With history of Type 1 diabetes or Type 2 diabetes\n* With chronic preexisting life-threatening conditions including pancreatic cancer, end-stage kidney dysfunction, and psychosis\n* Unable to read or speak English","45 Years",{"count":197,"type":22},800,"OBSERVATIONAL","Gestational diabetes mellitus (GDM) is a transient hyperglycemic condition identified during pregnancy in women without a history of chronic diabetes. Evidence indicates that GDM can lead to various adverse health outcomes, including preterm birth, progression to pre-diabetes, and type 2 diabetes after delivery in mothers. Notably, GDM is becoming increasingly prevalent among Asian pregnant women due to rising rates of overweight and obesity, as well as genetic susceptibility. Despite growing recognition of GDM, its treatment efficiency and efficacy remain poor, primarily due to its heterogeneity, which is underpinned by various pathophysiological mechanisms.\n\nTherefore, a better understanding of GDM heterogeneity can aid clinicians in providing more targeted treatment and follow-up strategies for GDM mothers. This study aims to define GDM phenotypes based on in vivo cardio-metabolic profiles and treatment response during pregnancy, utilizing advanced technologies such as continuous glucose profiling and untargeted metabolite profiling. In this proposed 3-year pregnancy cohort study, the investigators will recruit 800 overweight or obese Asian pregnant women in early pregnancy, without a history of diabetes, and follow them through to delivery. The goal of the study is to develop systematic antenatal and postnatal screening, treatment, and intervention guidelines for mothers with GDM.",[201,202,203,204,205,206],"Gestational Diabetes","Pregnancy Related","Pregnancy Complications","Birth Weight","Insulin Resistance, Diabetes","Intergenerational Relations",[208],"Pregnancy","2025-05-25",{"date":211,"type":33},"2025-05-28",{"date":213,"type":33},"2022-10-03",{"date":87,"type":22},{"name":39,"class":40},{"id":217,"slug":218,"hasResults":11,"nctId":219,"briefTitle":220,"officialTitle":221,"acronym":222,"eligibilityCriteria":223,"healthyVolunteers":11,"sex":48,"minAge":18,"maxAge":224,"enrollmentInfo":225,"targetDuration":4,"studyType":23,"phases":227,"briefSummary":228,"conditions":229,"keywords":231,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":242,"lastUpdatePostDateStruct":243,"startDateStruct":245,"completionDateStruct":246,"leadSponsor":248,"locationsCount":249},"100592933","the-effect-of-combined-transcranial-pulse-current-stimulation-tpcs-and-transcutaneous-electrical-nerve-stimulation-tens-on-lower-limb-motor-function-in-subacute-to-chronic-stroke-patients-with-hemiplegia-compensator-stroke-100592933","NCT06999876","The Effect of Combined Transcranial Pulse Current Stimulation (tPCS) and Transcutaneous Electrical Nerve Stimulation (TENS) on Lower Limb Motor Function in Subacute to Chronic Stroke Patients With Hemiplegia (COMPENSATOR-Stroke)","The Effect of Combined Transcranial Pulse Current Stimulation (tPCS) and Transcutaneous Electrical Nerve Stimulation (TENS) on Lower Limb Motor Function in Subacute to Chronic Stroke Patients With Hemiplegia: A Double-blind, Sham-controlled, Randomized Controlled Study","COMPENSATOR","Inclusion Criteria:\n\n1. Participants aged 21 years old and below 80 years old with a clinically diagnosed first onset ischaemic stroke confirmed by imaging modalities such as computerised tomography (CT) or magnetic resonance imaging (MRI). Previous transient ischemic attack or clinically silent infarct detected by CT\u002FMRI are not considered as previous stroke.\n2. Participants within the subacute stage of stroke (Within 14 days from stoke onset)\n3. Able to walk with or without assistance\n4. Able to understand instructions and give informed consent\n\nExclusion Criteria:\n\n1. History of craniotomy or placement of implant materials\u002F device in the body that may affect NIBS including, but not limited to, deep brain stimulator, cardiac implant, cochlear implant\n2. Intracranial haemorrhage in the cortical regions\n3. History of epilepsy or seizures\n4. History of major depression and a history of psychotic disorders\n5. Contraindications to tPCS\u002FTENS e.g., pregnancy, presence of skin lesion at the intended treatment areas.\n6. Concurrent use of benzodiazepine pyschoactive class of drugs which may affect effects of tPCS\n7. Concurrent use of anti-seizure medications (ASMs) which may affect effects of tPCS\n8. Presence of significant cognitive impairment\u002F aphasia rendering patient unable to comply with the treatment protocol\n9. Presence of disabling comorbidities that compromises limb function such as orthopaedics or neurological pathologies other than stroke\n10. Previous treatments of the lower limb spasticity with botulinum toxin, or alcohol.\n11. Prior history of non-invasive brain stimulations","79 Years",{"count":226,"type":22},90,[25],"The goal of this study is to evaluate the effects of high frequency tPCS + TENS compared to Sham device stimulation + TENS (Control) in lower limb motor function recovery in stroke patients with hemiplegia or hemiparesis in the subacute stage.The main questions it aims to answer are:\n\nPrimary objective - To evaluate the effects of high frequency tPCS + TENS compared to Sham device stimulation + TENS (Control) in lower limb motor function recovery, in stroke patients with hemiplegia or hemiparesis in the subacute stage\n\nSecondary Objectives -\n\n1. To evaluate the effects of high frequency tPCS + TENS in treatment of lower limb spasticity related to stroke.\n2. To evaluate the effects of high frequency tPCS + TENS in gait function improvement post stroke, including walking speed, mobility, balance and walking endurance.\n3. To evaluate the effects of high frequency tPCS on pain, mood and QOL.\n\nResearchers will compare the effects of high frequency tPCS + TENS to a control group which involves intervention with Sham device stimulation + TENS.\n\nParticipants will:\n\n* Be identified, recruited and have baseline assessments during screening period\n* First undergo a mandatory 2-hour device training at Visit 2 to ensure device competence.\n* Proceed with up to 7 days of habituation for device use and tolerability.\n* Carry out daily intervention sessions of 30 minutes for 30 days at home or inpatient setting.\n* Phone call follow-up (Telephone\u002F Video Call Interview) 2 weeks post intervention\n* Clinic visit at day 30 post intervention with allowance of + 7 days for study assessments\n* Clinic visit at day 90 post intervention with allowance of +\u002F- 7 days for study assessments\n* Update study coordinators via messaging platforms with regards to device issues, adverse events, any other reporting or questions",[230],"Stroke Patients With Hemiplegia or Hemiparesis in the Subacute Stage",[232,233,234,235,236,237,238,239,240,241],"Transcranial Pulsed Current Simulation","Transcutaneous Electrical Nerve Stimulation","Lower limb motor function recovery","Spasticity","Gait dysfunction","Standing balance","Ambulation","Stroke","Hemiplegia","Hemiparesis","2025-05-23",{"date":244,"type":33},"2025-05-31",{"date":244,"type":22},{"date":247,"type":22},"2026-12-31",{"name":39,"class":40},2,""]